Breakthrough nasal spray tested for rapid relief in suicidal teens

NCT ID NCT07227454

Recruiting now Symptom relief Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

Summary

This study is testing whether adding a nasal spray called esketamine to standard mental health care can quickly reduce severe depression and suicidal thoughts in teenagers. About 258 adolescents who are experiencing an acute suicidal crisis will receive either the active nasal spray or a placebo spray, along with comprehensive standard care. The main goal is to see if the treatment leads to a significant reduction in depression symptoms within 24 hours.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEPRESSIVE DISORDER, MAJOR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Peachford Hospital-Atlanta Behavioral Research
RECRUITING

Atlanta, Georgia, 30338, United States
University of Cincinnati
RECRUITING

Cincinnati, Ohio, 45219, United States

Conditions

Explore the condition pages connected to this study.

DEPRESSIVE DISORDER, MAJOR